Head to Head Survey: VolitionRx (NYSE:VNRX) versus Meridian Bioscience (NASDAQ:VIVO)

VolitionRx (NYSE:VNRXGet Rating) and Meridian Bioscience (NASDAQ:VIVOGet Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Analyst Ratings

This is a summary of recent recommendations for VolitionRx and Meridian Bioscience, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VolitionRx 0 0 1 0 3.00
Meridian Bioscience 0 0 1 0 3.00

Meridian Bioscience has a consensus target price of $30.00, suggesting a potential upside of 13.77%. Given Meridian Bioscience’s higher probable upside, analysts plainly believe Meridian Bioscience is more favorable than VolitionRx.

Profitability

This table compares VolitionRx and Meridian Bioscience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VolitionRx -29,465.93% -110.92% -80.49%
Meridian Bioscience 19.14% 18.45% 13.42%

Insider and Institutional Ownership

11.5% of VolitionRx shares are owned by institutional investors. Comparatively, 94.5% of Meridian Bioscience shares are owned by institutional investors. 15.4% of VolitionRx shares are owned by insiders. Comparatively, 2.3% of Meridian Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares VolitionRx and Meridian Bioscience’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VolitionRx $90,000.00 1,607.28 -$26.82 million ($0.50) -5.38
Meridian Bioscience $317.90 million 3.61 $71.41 million $1.36 19.39

Meridian Bioscience has higher revenue and earnings than VolitionRx. VolitionRx is trading at a lower price-to-earnings ratio than Meridian Bioscience, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

VolitionRx has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Comparatively, Meridian Bioscience has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.

Summary

Meridian Bioscience beats VolitionRx on 8 of the 11 factors compared between the two stocks.

About VolitionRx (Get Rating)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.

About Meridian Bioscience (Get Rating)

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.